The Correlation between Serum Levels of Anti-Toxoplasma gondii Antibodies and the Risk of Diabetes

  • Maryam KHALILI Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran and Dept. of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  • Mahmoud MAHAMI-OSKOUEI Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran and Dept. of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  • Abbas SHAHBAZI Dept. of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
  • Abdolrasoul SAFAIYAN Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran and Dept. of Biostatistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
  • Nader MOHAMMADZADEH-GHESHLAGHI Central Medical Laboratory of East Azerbaijan Province, Tabriz University of Medical Sciences, Tabriz, Iran
  • Leyla MAHAMI-OSKOUEI Dept. of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Keywords: Diabetes mellitus, Toxoplasma gondii, Chemiluminescence, Immunoassay

Abstract

Background: This study investigated the presence of specific antibodies against Toxoplasma gondii infection among people with diabetes (type I and II) in comparison with control group. Methods: Overall 300 serum samples were collected equally from three groups including patients with type I and type II diabetes and non-diabetic healthy control that referred to Tabriz Central Laboratory in northwest Iran during July to Sep 2015. The level of specific IgG and IgM antibodies against T. gondii were measured using the chemiluminescence immunoassay (CLIA) method. Chi-square and One-Way ANCOVA were used for data analysis. Results: Overall, 300 samples from diabetic patients (type I and type II) and control group were examined and results showed 3, 8 and 2 cases were seropositive for anti- T. gondii IgM respectively. Anti- T. gondii IgG seropositivity in type I and type II diabetes and control groups were 69%, 63% and 59% respectively. We did not observe any statistical differences among all studied groups in terms of toxoplasmosis. There was no statistically significant relationship between all variables and seropositivity for anti-T. gondii antibodies in type I and II diabetes and non-diabetic groups. Conclusion: Although there was no statistically significant relationship between diabetes and toxoplasmosis further investigations especially experimental studies using animal models are needed. Furthermore, these findings would not be contrary to the need for healthcare in order to the prevention of infectious disease in diabetic patients.

References

1. Tenter AM, Heckeroth AR, Weiss LM.. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000; 30(12-13):1217-58.
2. Mahami-Oskouei M, Moradi M, Fallah E, Hamidi F, Asl Rahnamaye Akbari N. Molecular detection and genotyping of Toxoplasma gondii in chicken, beef, and lamb meat consumed in northwestern Iran. Iran J Parasitol. 2017; 12(1):38-45.
3. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect. 2002; 8(10):634-40.
4. Wong SY, Remington JS. Toxoplasmosis in pregnancy. Clin Infect Dis. 1994; 18(6):853-61; quiz 62.
5. Elmore SA, Jones JL, Conrad PA, Patton S, Lindsay DS, Dubey JP. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010; 26(4):190-6.
6. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009; 39(12):1385-94.
7. Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol. 2008; 38(11):1257-78.
8. Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, Rahimi MT, Sharif M. Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta Trop. 2014; 137:185-94.
9. Torgerson PR, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull World Health Organ. 2013; 91(7):501-8.
10. Alavi SM, Alavi L. Toxoplasmosis in Iran : a guide of general physicians working in the Iranian health network setting: a systematic review. Caspian J Intern Med. 2016; 7(4):233-241.
11. Mohraz M, Mehrkhani F, Jam S et al. Seroprevalence of toxoplasmosis in HIV(+)/AIDS patients in Iran. Acta Med Iran. 2011; 49(4):213-8.
12. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87(1):4-14.
13. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012; 16 Suppl 1:S27-36.
14. Prandota J. T. gondii infection acquired during pregnancy and/or after birth may be responsible for development of both type 1 and 2 diabetes mellitus. J Diabetes Metab. 2013; 4:241.
15. Cumali Goekce SY, Fahri Bayram, Kursat Gundogan. Toxoplasma gondii antibodies in type 1 diabetes mellitus. Turkiye Klinikleri J Med Sci. 2008; 28(5):619-22.
16. Majidiani H, Dalvand S, Daryani A, Galvan-Ramirez ML, Foroutan-Rad M. Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case-control studies. Braz J Infect Dis. 2016; 20(6):605-609.
17. Mahami-Oskouei M, Hamidi F, Talebi M et al. Toxoplasmosis and Alzheimer: can Toxoplasma gondii really be introduced as a risk factor in etiology of Alzheimer? Parasitol Res. 2016; 115(8):3169-74.
18. Mahmoudvand H, Sheibani V, Shojaee S, Mirbadie SR, Keshavarz H, Esmaeelpour K, Keyhani AR, Ziaali N. Toxoplasma gondii Infection Potentiates Cognitive Impairments of Alzheimer's Disease in the BALB/c Mice. J Parasitol. 2016;102(6):629-635.
19. Hamidi F, Etemadi J, Ghabouli Mehrabani N, Mahami Oskouei M, Motavalli R, Ardalan MR. Comparison of Toxoplasma gondii seropositivity in hemodialysis and peritoneal dialysis patients. J Coast Life Med. 2015; 3(8):621-2.
20. Mahami Oskouei M, Hamidi F, Talebi M et al. The correlation between Toxoplasma gondii infection and Parkinson's disease: a case-control study. J Parasit Dis. 2016; 40(3):872-6.
21. Shirbazou S, Delpisheh A, Mokhetari R, Tavakoli G. Serologic detection of anti Toxoplasma gondii infection in diabetic patients. Iran Red Crescent Med J. 2013; 15(8):701-3.
22. Saki J, Shafieenia S, Foroutan-Rad M. Seroprevalence of toxoplasmosis in diabetic pregnant women in southwestern of Iran. J Parasit Dis. 2016; 40(4):1586-1589.
23. Gokce C, Yazar S, Bayram F, Gundogan K. Toxoplasma gondii antibodies in type 1 diabetes mellitus. Turk Klin Tip Bilim. 2008; 28(5):619-22.
24. Siyadatpanah A, Tabatabaie F, Oormazdi H et al. Comparison of anti-Toxoplasma IgG and IgM antibodies determined by ELISA method in diabetic and non-diabetic individuals in west Mazandaran province, Iran, 2011-2012. Ann Biol Res. 2013; 4(6):281-5.
25. Alvarado-Esquivel C, Loera-Moncivais N, Hernandez-Tinoco J et al. Lack of association between Toxoplasma gondii infection and diabetes mellitus: a matched case-control study in a mexican population. J Clin Med Res. 2017; 9(6):508-511.
Published
2018-12-22
How to Cite
1.
KHALILI M, MAHAMI-OSKOUEI M, SHAHBAZI A, SAFAIYAN A, MOHAMMADZADEH-GHESHLAGHI N, MAHAMI-OSKOUEI L. The Correlation between Serum Levels of Anti-Toxoplasma gondii Antibodies and the Risk of Diabetes. IJPA. 13(4):637-42.
Section
Short Communication(s)